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ABSTRACT
Objectives: The aim of this study was to present strategy and early results of treatment of advanced cervical cancer patients 
with synchronous cancers observed in PET-CT imaging, treated at the Greater Poland Cancer Center.
Material and methods: The study included a group of 200 patients with diagnosed stage IIB-IIIB cervical cancer who 
received PET-CT for the purpose of radiotherapy treatment planning.
Results: Among our study group, four patients (2%) were found to have a synchronous cancer. Two of the cases were 
diagnosed as breast cancer. However, cancers diagnosed in the other two patients were head and neck malignancies 
— hypopharyngeal and laryngeal cancer. The choice of an optimal therapeutic approach requires taking into account 
characteristics of particular malignancies, their stage and histopathology. The whole therapy included radiotherapy of 
cervical cancer with various combinations of systemic treatment, radiotherapy or surgery of synchronous cancer. According 
to treatment results, patients diagnosed with breast cancer and hypopharyngeal cancer achieved complete remission of 
both primary and secondary tumour. Patient diagnosed with laryngeal malignancy, despite achieving complete remission 
of cervical cancer, finished radiotherapy of the synchronous cancer at a palliative dose.
Conclusions: The growing availability of PET-CT and other imaging methods in cancer diagnosis will increase the number 
of diagnosed synchronous cancers. Second primary cancers are often detected at an early stage, where radical treatment 
can be performed for both primary and secondary tumour. However, treatment of such complicated clinical cases as syn-
chronous cancers should be carried out by multidisciplinary teams.
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INTRODUCTION
Second Primary Cancers (SPCs) are new, primary inde-
pendent cancer foci. Timeframes that allow to categorize 
them into synchronous and metachronous cancers differ de-
pending on authors. The SEER (Surveillance, Epidemiology, 
and End Results) register held by the U.S. National Cancer 
Institute (NCI) defines synchronous cancer as a second focus 
diagnosed within two months of the primary malignancy [1]. 
Further independent tumour foci diagnosed after that time 
are referred to as metachronous cancers. The International 
Agency for Research on Cancer sets the border line between 
synchronous and metachronous cancer at six months [2]. 
This study assumes the period of two months as a timeframe 
for synchronous cancer diagnosis.
Diagnosis of synchronous cancer is closely associated 
with thorough interview and physical examination as well 
as the use of additional diagnostic tests. Of particular im-
portance for determining the clinical stage of the tumour 
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are Computed Tomography (CT) and Magnetic Resonance 
Imaging (MRI). Increasingly, Positron Emission Tomography 
(PET-CT) is also performed where fluorodeoxyglucose-based 
metabolic activity assessment allows to detect a primary 
focus, metastatic foci as well as other neoplasms. 
At the Greater Poland Cancer Center, PET-CT scans are 
performed in patients, treated with radical radiochemo-
therapy or radiotherapy for advanced cancer of the cervix, 
for the purpose of optimalisation radiotherapy treatment 
planning. In over 35% of the patients, the stage of the dis-
ease as determined by the PET-CT imaging was significantly 
different from that found in clinical examination, which 
led to restaging of the disease and change of the planned 
therapeutic approach by including systemic treatment in 
various combinations with radiotherapy.
OBJECTIVES
The aim of this study was to present strategy and early 
results of treatment of advanced cervical cancer patients 
diagnosed with synchronous cancers in PET-CT imaging, 
treated at the Greater Poland Cancer Center.
MATERIAL AND METHODS
The study conducted in 2011–2015 included a group of 
200 patients with diagnosed stage IIB–IIIB cervical cancer 
who received PET-CT. The examination employed a hybrid 
scanner comprising a PET and transmission CT scanner 
(Gemini TF). The acquisition was made 60 minutes after 
intravenous injection of 300 MBq 18-fluorodeoxyglucose 
in patients who had had an empty stomach for at least 
5 hours. The injection was preceded by the evaluation of glu-
cose concentration in blood serum which could not exceed 
8.33 mmol/L (150 mg/dL) during the examination. The ac-
quisition was performed from the skullcap to the mid-thighs 
with CT (120 keV, 50 mAs) followed by PET (100 sec./9 cm 
body section). Data obtained were reconstructed based on 
iterative techniques using the time-of-flight technology 
to receive cross-sections in the three standard planes. To 
evaluate the pathological changes, the metabolic activity 
of the changes was assessed based on the SUVmax value.
In our study group, four patients (2%) were found to 
have a synchronous cancer which was confirmed histo-
pathologically. Each of the four patients was found to have 
carcinoma of the cervix in stage IIIB according to the Interna-
tional Federation of Gynecology and Obstetrics (FIGO). Two 
of the cases were diagnosed as early stage breast cancer, 
confirmed in mammography. In Poland, the most common 
cancer locations in women are, in descending order, breast, 
lungs and endometrium [3]. However, the other two patients 
with diagnosed synchronous tumours had head and neck 
cancers which account for a low proportion of all diagnosed 
malignancies in women (approx. 1.4%) [3]. In one of them, 
the stage of the H & N cancer excluded surgery, while the 
other patient refused the proposed surgery and chose radio-
therapy instead. Patient characteristics are shown in Table 1.
In addition to the above mentioned four cases, one of 
the 200 patients studied, with diagnosed stage IIB cervical 
cancer, was treated for invasive cancer of the left breast. 
Metastatic lesions in the lungs were found by PET. The 
changes in the PET image, stage of primary breast can-
cer and molecular subtype indicated that the lesions had 
originated from the previously treated cancer of the left 
breast. This conclusion is also supported by the fact that the 
patient, following breast cancer surgery, did not undergo 
the planned adjuvant chemotherapy and radiotherapy due 
to the detection of cancer of the cervix. No biopsy of the 
metastatic lesions was performed.
Another patient had pancreatic cancer, treated pal-
liatively by stenting of biliary ducts, diagnosed within six 
months preceding the cervical cancer treatment. PET imag-
ing confirmed the existence of an active neoplastic process 
within the head of pancreas, metastatic lymph nodes and 
metastatic foci in the bones. According to some studies and 
data sets, such a time interval would also allow those two 
processes to be classified as synchronous cancers.
The characteristics of the patients are shown in Table 2.
Table 1. Characteristics of synchronous cancer patients
No. Age Stage of cervical cancer
Histopathology  
of cervical cancer
Synchronous cancer  
and stage Histopathology of synchronous cancer
1 66 IIIB Carcinoma planoepitheliale microcellulare akeratodes
Cancer of the left breast, 
pT1c, pN0(sn)
Invasive breast cancer (NST/ductal with 
features of cribriform and tubular pattern) 
NHG1; ER(+), PgR(+), HER2(–)
2 63 IIIB Carcinoma planoepitheliale akeratodes G2
Cancer of the left breast, 
pT1c, pN1a
Invasive breast cancer (NST) NHG1; ER(+), 
PgR(+), HER2(–)
3 69 IIIB Carcinoma male differentiatum colli uteri G3
Hypopharyngeal cancer, 
T4bN2cM0
Non-keratinising squamous cell 
carcinoma G2
4 61 IIIB Carcinoma planoepitheliale non keratodes G3
Laryngeal cancer, 
T2N2bM0
Non-keratinising squamous cell 
carcinoma G3
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Treatment
The choice of an optimal therapeutic strategy requires 
characteristics of particular malignancies to be taken into 
account, including their stage and histopathology. In the 
case of the above discussed patients, each decision on what 
diagnostic and therapeutic approach to take was made 
by a multidisciplinary team (MDT) of gynaecological on-
cologists, clinical oncologists and radiation oncologists. The 
treatment took into account the occurrence of two cancers, 
which required that a parallel therapy be used to cover 
both of them. 
A detailed protocols applied in the patients and par-
ticular stages in the treatment of the primary cancer and 
synchronous cancers are shown in Table 3.
Patient 1
In the case of the first patient analysed, PET-CT showed 
a metabolically active tumour of the cervix and body of 
the uterus with features of a proliferative process and 
metastases to the iliac and paraaortic lymph nodes and 
a nodule in the left breast with features of a malignant 
process. In mammography, the nodule was evaluated as 
BIRADS 5. Breast cancer was confirmed in a fine needle 
aspiration biopsy (FNAB). Due to the advanced stage of 
cervical cancer (IIIB), metastases to the paraaortic lymph 
nodes and the co-occurrence of a second cancer, the pa-
tient received, at the first stage, an independent systemic 
treatment, i.e. neoadjuvant chemotherapy. It involved cy-
tostatics adequate for the treatment of both breast cancer 
and cervical cancer. Then, quadrantectomy was performed 
with a sentinel node biopsy (SNB). After two weeks, a radical 
radiotherapy was performed targeted against the tumour 
of the cervix — teleradiotherapy, brachytherapy and hy-
perthermia. Then, the patient was treated with adjuvant 
radiotherapy for breast cancer. Further treatment involved 
adjuvant hormonal therapy.
Patient 2
PET-CT of the next patient showed a metabolically ac-
tive proliferation in the cervix uteri with features of prolif-
erative process and without features of spread. The patient 
began a radical radiotherapy due to diagnosed advanced 
cancer of the cervix (IIIB). It involved tele- and brachytherapy 
and weekly administrations of cisplatin. Due to a poor toler-
ance to chemotherapy, cytostatic treatment was terminated 
after the administration of the first cycle of cisplatin. The 
Table 2. Characteristics of patients with cervical cancer and other previously diagnosed cancer
No. Age Stage of cervical cancer
Histopathology  
of cervical cancer
Second cancer: primary 
stage and histopathology
Second cancer: clinical status  
at PET test
5 51 IIB Carcinoma planoepitheliale typus keratodes
Invasive cancer of the left 
breast (ductal type) 
NHG2, pT2, pN0(sn); 
ER(+), PgR(+), HER2(+++)
Metastases of the left breast cancer to 
the lungs 
6 36 IIIB Carcinoma neuroendocervicale microcellulare
Pancreatic cancer T4 N1 M1; 
Cellulae carcinomatosae 
(fine needle biopsy)
Persistent infiltration within the head of 
pancreas, metastatic lymph nodes and 
distant metastases to the skeletal system
Table 3. Stages and methods of treatment of synchronous cancer patients
No. Age Treatment stage I Treatment stage II Treatment stage III Treatment stage IV Treatment stage V
1 66
Neoadjuvant chemotherapy 
(paclitaxel + cisplatin; 
6 courses)
Breast conserving 
surgery (BCS) with 
sentinel node biopsy 
(SNB)
Radical radiotherapy 
for cervical 
cancer + 2 hyperthermia 
procedures
Adjuvant breast 
cancer radiotherapy
Adjuvant hormonal 
therapy (in progress)
2 63
Radical radiochemotherapy 
for cervical cancer (cisplatin; 
1 course) + 2 hyperthermia 
procedures
Breast conserving 
surgery with axillary 
lymph node dissection
Adjuvant breast cancer 
radiotherapy
Adjuvant hormonal 
therapy (in 
progress)
3 69 Radical radiotherapy for cervical cancer
Palliative radiotherapy 
for hypopharyngeal 
cancer 
4 61
Radical radiotherapy 
for cervical cancer with 
simultaneous chemotherapy 
(paclitaxel + cisplatin; 
3 courses at 4-week intervals)
Radical radiotherapy for 
laryngeal cancer
478
Ginekologia Polska 2017, vol. 88, no. 9
www. journals.viamedica.pl/ginekologia_polska
treatment was completed with radiotherapy plus hyper-
thermia. Mammography was performed during radiation 
therapy to reveal a lesion in the right breast — BIRADS 5. 
Core needle biopsy confirmed the diagnosis of breast can-
cer. The lesion was not visible in the previously performed 
PET-CT imaging. After completion of cervical cancer treat-
ment, quadrantectomy was carried out with a left axillary 
lymph node dissection. Then, adjuvant radiotherapy for 
breast cancer was performed. Further treatment involved 
adjuvant hormonal therapy.
Patient 3
The changes observed in PET-CT imaging in the third 
patient involved a proliferation in the cervix with features 
of a malignant process and hypermetabolic infiltration of 
the posterior wall of the hypopharynx with features in-
dicating a second focus of a primary malignant process 
with metastases to the left cervical lymph nodes. Biopsy 
of the lesion confirmed the diagnosis of squamous cell 
carcinoma. Due to obstructive nephropathy and emergent 
unilateral nephrostomy, a decision was made to refrain 
from a combined systemic treatment. The patient was quali-
fied for a stand-alone radical cervical cancer radiotherapy. 
When the therapy was finished, the patient was qualified 
for radical radiotherapy of the detected synchronous cancer 
because of the advanced stage of her pharyngeal cancer. 
During hospitalisation, accumulation of fluid in the pleural 
cavity was observed. Cytology of the fluid confirmed the 
presence of cancer cells. It was impossible to clearly deter-
mine the origin of the metastasis to the pleura. Therefore, 
radiotherapy of the hypopharynx was finished at a palliative 
dose (36 Gy). The patient was discharged from hospital with 
recommendation for palliative care at home. According to 
the information obtained, the patient died two months after 
the completion of palliative radiotherapy.
Patient 4
A pre-treatment PET-CT performed in the fourth patient 
showed a metabolically active cervical tumour with fea-
tures of a malignant process and metastases to iliac lymph 
nodes. Furthermore, a metabolically active infiltration of 
the larynx was found with features of a second focus of the 
primary proliferative process with metastases to the left 
cervical lymph nodes. The stage of cancer was assessed in 
CT. In biopsy, fragments of laryngeal squamous mucosa 
were found with reactive changes, without dysplasia. The 
patient started a radical radiotherapy for cancer of the cer-
vix. As clinical symptoms persisted (chronic hoarse voice), 
another biopsy of the tumour was performed. It confirmed 
the diagnosis of laryngeal squamous cell carcinoma. A sys-
temic treatment was started. The cytostatics used acted 
against both cervical and laryngeal cancer. Following the 
treatment, a total laryngectomy was proposed. The patient 
refused to be operated and, therefore, was subjected to 
a stand-alone radical radiotherapy for laryngeal carcinoma 
using the tomotherapy technique.
Particular treatment stages of the above discussed two 
patients with previously diagnosed cancer are shown in 
Table 4.
Patient 5
In the other study group, PET-CT performed in the above 
discussed patient indicated a hypermetabolic infiltration 
of the cervix with metastases to external iliac lymph nodes 
and metabolically active nodules in both lungs with fea-
tures of metastasis, probably from breast cancer. A decision 
was taken to conduct a radical radiotherapy for tumour of 
the cervix involving tele- and brachytherapy. Then, patient 
received chemotherapy in order to treat the metastatic le-
sions. After the completion of the first line chemotherapy, 
a chest CT showed the progression of the disease. Hormonal 
therapy was changed from tamoxifen to aromatase inhibi-
tor. A follow-up PET scan revealed a complete metabolic 
response to the treatment of cervical tumour and meta-
static lymph nodes in the abdominal cavity and a partial 
metabolic response to the treatment of nodular lesions in 
both lungs. The patient started second line chemotherapy. 
The next chest CT indicated the progression of pulmonary 
lesions. Additionally, MRI revealed metastases to the brain. 
The patient received a palliative radiotherapy for meta-
static cerebral lesions. A decision was made to apply a third 
line chemotherapy. The systemic treatment regimen was 
changed due to pancytopenia. Currently, the patient is un-
dergoing her fourth line systemic treatment.
Table 4. Stages and methods of treatment of patients with other previously diagnosed cancer
No. Age Treatment stage I Treatment stage II Treatment stage III Treatment stage IV
5 51 Radical radiotherapy for cervical cancer
Chemotherapy of metastatic 
lesions: TAC (6 courses), 
herceptin and capecitabine 
(9 courses)
Palliative radiotherapy for 
brain metastasis
Chemotherapy continuation: 
gemcitabine and carboplatin 
(18 courses), vinorelbine (in 
progress)
6 36
Chemotherapy involving 
etoposide and cisplatin 
(7 courses)
Palliative radiotherapy for 
cervical cancer
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Patient 6
Imaging (ultrasound, CT) performed in the patient with 
diagnosed concurrent pancreatic cancer displayed massive 
lymph node lesions within the abdominal cavity. Chemo-
therapy was delivered. Follow-up PET revealed persisting 
lymph node lesions within the small pelvis and abdominal 
cavity, an active process in the head of pancreas and meta-
static lesions in the bony structure. Palliative radiotherapy 
for cancer of the cervix was performed.
RESULTS
The result analysis of the treatment of the six patients 
is shown in Table 5.
DISCUSSION
Imaging methods, which are becoming increasingly com-
mon, allow a precise assessment of primary cancer stage and 
often detect synchronous cancers. In a study of Scottish epide-
miologic registries, new cancers were found to develop in 5% 
of 57,000 patients. Among those patients, synchronous cancer 
was diagnosed in 28% simultaneously or within two months. In 
that report, the most common malignancy, both primary and 
secondary, was lung cancer. Breast cancer was the third most 
common secondary cancer in all the study group [4].
In view of the increasing availability of PET-CT imaging 
in cancer diagnosis, synchronous neoplasms are more often 
detected. Ishimori et al. published a report on 1900 patients 
with diagnosed or suspected primary cancer who received 
PET-CT. In 1.2% of the patients, second primary cancers were 
found and confirmed by histopathology [5].
PET-CT tests used at the Greater Poland Cancer Center 
in inoperative cervical cancers for teleradiotherapy treat-
ment planning indicated the occurrence of second primary 
cancers, which had not been detected before, in 2% of the 
patients. A Korean study conducted by Tong et al. related to 
the incidence of synchronous cancers in women with diag-
nosed with gynaecological cancer [6]. Out of 3,100 patients 
included, synchronous cancer was found in 0.63%. The most 
common primary malignancy was cancer of the endome-
trium concurrent with ovarian cancer and cervical cancer. 
A Japanese study including 1,000 patients with gynaecologi-
cal cancers reported the coexistence of a second primary 
cancer in 4.3% patients, of whom 38% had synchronous can-
cers. The most common secondary malignancy was breast 
cancer [7]. In a Turkish series including 4,000 women with 
primary gynaecological cancer, 1.3% were found to have 
synchronous or metasynchronous cancers. The most com-
mon concomitant cancers were those of the endometrium 
and ovary [8]. Other Turkish studies report that the most 
common concomitant primary cancers in women are breast 
cancer as a primary malignancy and gynaecological can-
cer as a second independent malignancy [9]. In the above 
presented report from the Greater Poland Cancer Center, 
advanced cervical cancer coexisted most often with breast 
cancer which is the most prevalent cancer in Polish wom- 
en [2]. Additionally, head and neck cancers, i.e. hypopharyn-
geal and laryngeal carcinoma, were also found.
In the case of two or more synchronous tumours being 
diagnosed, it is of key importance to choose an appropri-
ate treatment, particularly in the case of chemotherapy 
optimally targeted at both primary tumours. The sequence 
of treatments in particular synchronous cancers in the cases 
described was primarily adapted to therapeutic possibili-
ties and clinical stage. The first patient received neoad-
juvant systemic treatment. It comprised cytostatics used 
both in the treatment of cancer of the cervix and induction 
Table 5. Treatment results for patients studied
No. Cancer type Result after treatment Duration of follow-up  (as of Jan. 2017) [months] Result after follow-up
1
Cervical cancer Complete remission 20 Complete remission
Breast cancer Complete remission 18 Complete remission
2
Cervical cancer Complete remission 32 Complete remission
Breast cancer Complete remission 27 Complete remission
3
Cervical cancer Complete remission
Patient’s death
Hypopharyngeal cancer Partial remission
4
Cervical cancer Complete remission 12 Complete remission
Laryngeal cancer Complete remission 9 Complete remission
5
Cervical cancer Complete remission 45 Complete remission
Breast cancer Complete remission 49 Progression — chemotherapy in progress
6
Cervical cancer Partial remission No data No data
Pancreatic cancer Progression No data No data
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chemotherapy for breast cancer [10, 11]. In the case of the 
fourth patient, systemic treatment was started parallel to 
cervical cancer radiotherapy. Notably, the chemotherapy 
regimen applied differed from the one commonly chosen 
(cisplatin — single dose of 40 mg/m2 at 7-day intervals). 
Instead, 135 mg/m2 paclitaxel was used in combination with 
75 mg/m2 cisplatin at 4-week intervals. This approach was 
dictated by the concomitant synchronous laryngeal cancer 
whose treatment requires cisplatin [12].
That SEER-based study indicates that cervical cancer 
patients are at an increased risk of secondary cancers, mainly 
associated with cervical cancer risk factors. In women with 
HPV virus infection, these were mostly cancers of the vagina, 
vulva and anus. The above analysis of secondary cancer 
risk does not include the synchronous/metasynchronous 
division. The authors also took note of an increased risk of 
secondary cancers in patients treated with radiotherapy for 
cervical cancer [13]. Another study of the same register, this 
time in terms of synchronous malignancies only, showed 
them to be present in 1.96% of cancer patients. In over 88% 
of them, synchronous cancers were diagnosed at the same 
time as primary cancers [14].
Considering that synchronous cancers are often de-
tected at early stage, it is possible to treat them radically 
[15–18]. The role of diagnostic and therapeutic interdisci-
plinary teams is paramount in this case. The integration of 
knowledge and experience of experts in various disciplines, 
in this case gynaecological oncology, clinical oncology, ra-
diation oncology, radiology and pathomorphology, enables 
a fully comprehensive and personalised diagnostic and 
therapeutic process. Treatment protocols are prepared and 
adjusted to the needs of particular patients, which is of 
particular importance for synchronous cancers.
CONCLUSIONS
The growing availability of PET-CT and other imaging 
methods will surely increase the number of diagnosed syn-
chronous cancers.
In the collected material, out of four synchronous can-
cers, two (50%) were breast cancer cases. Interestingly, can-
cers diagnosed in the other two patients were head and neck 
malignancies which are relatively rare in the population of 
Polish women.
A note should be taken that according to treatment 
results shown in Table 5, despite diagnosed synchronous 
cancer concomitant with advanced cervical cancer, com-
plete remission of both malignancies was achieved in three 
patients. That was possible mainly because of early de-
tection of the synchronous tumours, where radical and 
personalised treatment, targeted at both types of cancer, 
can be performed.
Treatment of such complicated clinical cases as syn-
chronous cancers should be carried out at institutions that 
have multidisciplinary diagnostic and therapeutic teams 
to perform that kind of therapy. PET-CT seems to be a uni-
versal diagnostic method which, apart from determination 
of primary cancer stage, allows to identify the presence of 
a second cancer.
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